{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:50:25Z","timestamp":1787032225850,"version":"build-2736575974"},"reference-count":22,"publisher":"Becaris Publishing Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,7]]},"abstract":"\n Background:<\/jats:bold>\n Eligibility criteria are pivotal in achieving clinical trial success, enabling targeted patient enrollment while ensuring the trial safety. However, overly restrictive criteria hinder enrollment and study result generalizability. Broadening eligibility criteria enhances the trial inclusivity, diversity and enrollment pace. Liu\n et al.<\/jats:italic>\n \u00a0proposed an AI pathfinder method leveraging real-world data to broaden criteria without compromising efficacy and safety outcomes, demonstrating promise in non-small cell lung cancer trials.\n Aim:<\/jats:bold>\n To assess the robustness of the methodology, considering diverse qualities of real-world data and to promote its application.\n Materials\/Methods:<\/jats:bold>\n We revised the AI pathfinder method, applied it to relapsed and refractory multiple myeloma trials and compared it using two real-world data sources. We modified the assessment and considered a bootstrap confidence interval of the AI pathfinder to enhance the decision robustness.\n Results & conclusion:<\/jats:bold>\n Our findings confirmed the AI pathfinder's potential in identifying certain eligibility criteria, in other words, prior complications and laboratory tests for relaxation or removal. However, a robust quantitative assessment, accounting for trial variability and real-world data quality, is crucial for confident decision-making and prioritizing safety alongside efficacy.\n <\/jats:p>","DOI":"10.57264\/cer-2023-0164","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T11:16:19Z","timestamp":1718277379000},"source":"Crossref","is-referenced-by-count":8,"title":["Evaluating the robustness of an AI pathfinder application on eligibility criteria in multiple myeloma trials using real-world data and historical trials"],"prefix":"10.57264","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0607-2801","authenticated-orcid":false,"given":"Rana","family":"Jreich","sequence":"first","affiliation":[{"name":"R&D, Evidence Generation\u00a0& Decision Sciences, Sanofi, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medical College, Cornell University, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoling","family":"Meng","sequence":"additional","affiliation":[{"name":"R&D, Evidence Generation\u00a0& Decision Sciences, Sanofi,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medical College, Cornell University, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"11","key":"e_1_3_7_3_2","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review","volume":"297","author":"Van Spall HGC","year":"2007","unstructured":"Van Spall HGC, Toren A, Kiss A Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 297(11), 1233\u20131240 (2007).","journal-title":"JAMA"},{"issue":"17","key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/djq291","article-title":"A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program","volume":"102","author":"Scoggins JF","year":"2010","unstructured":"Scoggins JF, Ramsey SD. A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. J. Natl Cancer Inst. 102(17), 1371\u20131371 (2010).","journal-title":"J. Natl Cancer Inst."},{"issue":"9","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1078-0432.CCR-20-3852","article-title":"Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO-friends of cancer research joint research statement","volume":"27","author":"Kim ES","year":"2021","unstructured":"Kim ES, Uldrick TS, Schenkel C Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO-friends of cancer research joint research statement. Clin. Cancer Res. 27(9), 2394\u20132399 (2021).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"106515","DOI":"10.1016\/j.cct.2021.106515","article-title":"Eligibility criteria and clinical trials: An FDA perspective","volume":"109","author":"Duggal M","year":"2021","unstructured":"Duggal M, Sacks L, Vasisht KP. Eligibility criteria and clinical trials: An FDA perspective. Contemp. Clin. Trials 109, 106515 (2021).","journal-title":"Contemp. Clin. Trials"},{"key":"e_1_3_7_7_2","unstructured":"FDA services US department of Health and Human. Enhancing the diversity of clinical trial populations-eligibility criteria enrollment practices and trial design guidance for industry. Available at: https:\/\/www.federalregister.gov\/documents\/2020\/11\/10\/2020-24881\/enhancing-the-diversity-of-clinical-trial-populations-eligibility-criteria-enrollment-practices-and# (2020)."},{"issue":"7855","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41586-021-03430-5","article-title":"Evaluating eligibility criteria of oncology trials using real-world data and AI","volume":"592","author":"Liu R","year":"2021","unstructured":"Liu R, Rizzo S, Whipple S Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature 592(7855), 629\u2013633 (2021).","journal-title":"Nature"},{"key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"104032","DOI":"10.1016\/j.jbi.2022.104032","article-title":"Leveraging electronic health record data for clinical trial planning by assessing eligibility criteria's impact on patient count and safety","volume":"127","author":"Rogers JR","year":"2022","unstructured":"Rogers JR, Pavisic J, Ta CN Leveraging electronic health record data for clinical trial planning by assessing eligibility criteria's impact on patient count and safety. J. Biomed. Inform. 127, 104032 (2022).","journal-title":"J. Biomed. Inform."},{"issue":"10245","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos M","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos MV Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 396(10245), 186\u2013197 (2020).","journal-title":"Lancet"},{"issue":"14","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos MA","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375(14), 1319\u20131331 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo A","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375(8), 754\u2013766 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos MA","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 22(6), 801\u2013812 (2021).","journal-title":"Lancet Oncol."},{"issue":"2","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart AK","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372(2), 142\u2013152 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau P","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 374(17), 1621\u20131634 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos MA","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 17(1), 27\u201338 (2016).","journal-title":"Lancet Oncol."},{"issue":"7","key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial S","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373(7), 621\u2013631 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1080\/10428194.2016.1180685","article-title":"Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)","volume":"57","author":"Moreau P","year":"2016","unstructured":"Moreau P, Weisel KC, Song KW Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). Leuk. Lymphoma 57(12), 2839\u20132847 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"e_1_3_7_19_2","unstructured":"Birnbaum B Nussbaum N Seidl-Rathkopf K Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. Available at: https:\/\/arxiv.org\/abs\/2001.09765"},{"key":"e_1_3_7_20_2","unstructured":"Ma X Long L Moon S Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health SEER and NPCR. Available at: https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.16.20037143v3"},{"key":"e_1_3_7_21_2","unstructured":"Optum\u00ae de-identified Electronic Health Record dataset (2007\u20132021)."},{"issue":"8","key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n MA","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183(8), 758\u2013764 (2016).","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"e_1_3_7_23_2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15(1), e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"issue":"2","key":"e_1_3_7_24_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu S","year":"2010","unstructured":"Xu S, Ross C, Raebel MA Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 13(2), 273\u2013277 (2010).","journal-title":"Value Health"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T07:15:57Z","timestamp":1720077357000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.57264\/cer-2023-0164"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0164","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"article-number":"e230164"}}